PARP Inhibitors Before Surgery: A New Treatment Option for Ovarian Cancer Patients? More Testing May Be Needed March 27, 2023By Rodrigo Edelmuth
The Drug Zejula Shows Important Long-Term, Progression-Free Survival Benefit For Patients With Advanced Ovarian Cancer October 13, 2022By Rodrigo Edelmuth
A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and Lymphomas September 9, 2022By
A Study to Evaluate Rucaparib in Patients With Solid Tumors and With Deleterious Mutations in HRR Genes August 4, 2022By
A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency July 6, 2022By
A Study of Rucaparib Versus Physician’s Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency March 24, 2022By
Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors February 17, 2022By
Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP) February 7, 2022By
PARP Inhibitors Quick Guide — Understanding The Different Drugs & Who May Benefit February 3, 2022By Noah Kotch
A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) December 27, 2021By
